JINZHEN for Treatment of Mild to Moderate COVID-19

COVID-19 Clinical Trial

Official title:

A Phase I/Ⅱ Randomized Controlled Proof-of-concept Study to Evaluate the Safety and Efficacy of JINZHEN Granules for Oral Solution in Participants With Mild to Moderate COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05092503
• Other study ID #: JZ-2001-01
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 26, 2022
• Est. completion date: May 12, 2023

Study information

• Verified date: March 2024
• Source: Lianyungang Kanion Group, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials. This study is to evaluate the safety and efficacy of JINZHEN Granules for Oral Solution compared to placebo for treatment of mild to moderate COVID-19 outpatients.

Description:

The study is a randomized, double-blind, placebo-controlled, proof of concept study with four groups (low dose treatment group, middle dose treatment group, high dose treatment group, and placebo group). Study eligibility will be assessed during screening. Study participants will be randomized in a 3:1 ratio to receive JINZHEN Granules for Oral Solution or placebo granules for 14 days.

During the 14-day clinical study, participants will be assessed daily at home using e-diary to collect clinical data and in person visit on Day 7 and Day14. All subjects will undergo a series of efficacy, safety, and laboratory assessments. Clinical observation endpoints will be assessed at day 7 and day 14. Interim analysis will be performed to evaluate efficacy and safety of 7-day and 14-day treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: May 12, 2023
• Est. primary completion date: May 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Adult = 18 years and = 50 years of age, BMI < 30 at time of enrollment.

2. Have presence of SARS-CoV-2 infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) test with sample collection = 3 days prior to randomization.

3. Fever = 38.0? (100.4? oral temperature) or = 38.6? (101.48? tympanic temperature) within 48 hours before screening; and at least one of respiratory rate > 24 breaths/minute or cough (scored = 2 via participant questionnaire).

4. Initial onset of signs/symptoms for = 5 days prior to randomization.

5. Participant provides written informed consent prior to initiation of any study procedures.

6. Participant is willing to accept randomization to any assigned treatment arm. And participant understands and agrees to comply with planned study procedures.

Exclusion Criteria:

1. SARS-CoV-2 infection confirmed participants who are currently hospitalized or are expected to need hospitalization (for COVID-19 within 48 hours of randomization).

2. Participants who have SpO2 ? 93% on room air at sea level, or respiratory frequency ? 30 breaths/minute, or heart rate = 125 per minute.

3. Require mechanical ventilation or anticipated impending need for mechanical ventilation.

4. Pre-existing pulmonary conditions such as chronic obstructive pulmonary disease or asthma. Imaging confirmed the existence of severe lung interstitial lesions, bronchiectasis, bronchopulmonary dysplasia and other basic pulmonary diseases. Have chronic pulmonary diseases such as pulmonary embolism and pulmonary hypertension at present.

5. Have any other active infectious diseases. Such as influenza, bacterial infections of the respiratory system (suppurative tonsillitis, acute tracheobronchitis, active tuberculosis, etc.) and other respiratory diseases affecting the evaluation of clinical trials.

6. ALT/AST > 3×ULN, TBIL = 1.5×ULN, creatinine = 1.5×ULN.

7. Patients with recurrent diarrhea or abnormal intestinal function that are not caused by COVID-19.

8. Patients with a history of type 1 or type 2 diabetes, OR with glycosylated hemoglobin (HbA1c) level = 6.5% during screening.

9. Patients with hypertension at screening (systolic blood pressure = 140 mmHg and/or diastolic blood pressure = 90 mmHg).

10. Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study. Such as, unresectable malignant tumor, blood disease, active bleeding, cachexia, nervous system disease, endocrine system disease, cardiovascular disease and heart conditions (e.g., heart failure [New York heart association (NYHA) = grade 3], coronary artery disease, cardiomyopathies), down syndrome, sickle cell disease, cystic fibrosis, thalassemia, etc.

11. Suffering from diseases that seriously affect the immune system, such as HIV infection, splenectomy, organ or blood stem cell transplantation, etc.

12. Participants who received systemic corticosteroids or other immunosuppressive medications within 14 days before screening.

13. Participants with positive results of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) at screening period.

14. Participants who are using any herb supplements/products.

15. Participants who are currently using anti-virus drugs.

16. Nursing women or women of pregnancy test positive or planning to be pregnant throughout the study period.

17. Psychiatric or cognitive illness (such as schizophrenia spectrum disorders, mood disorders, dementia, etc.) or alcohol abuse.

18. Participants who have received any interventional experimental treatment for COVID-19 within the 30 days prior to the time of the screening evaluation.

19. Participants unable to take oral medications.

20. Participants who plan to receive live attenuated vaccine within 1 month prior to the first administration of the study drug or during the study period.

21. Participants with mild to moderate COVID-19 who would be eligible for another FDA authorized COVID-19 therapeutic.

22. Participants who are on sensitive substrates or substrates of a narrow therapeutic range for major cytochrome P450 and transporters.

23. Other conditions inappropriate for participation in this clinical trial considered by the investigators.

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• JINZHEN Granules for Oral Solution
JINZHEN granules will be dissolved in drinking water and administered orally.
• Placebo
Placebo granules will be dissolved in drinking water and administered orally.

Locations

Country	Name	City	State
United States	F. Gabriel LLC	Bayonne	New Jersey
United States	Clearview Medical Research LLC	Canyon Country	California
United States	Carolina Institute for Clinical Research	Fayetteville	North Carolina
United States	AA Medical Research Center	Flint	Michigan
United States	Piedmont Research Partners	Fort Mill	South Carolina
United States	Family First Medical Research Center	Hialeah Gardens	Florida
United States	SMS Clinical Research	Mesquite	Texas
United States	LMG Research	Miami	Florida
United States	Frontier Clinical Research LLC	Morgantown	West Virginia
United States	Frontier Clinical Research LLC	Smithfield	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Lianyungang Kanion Group, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median time to sustained symptom resolution within 28 days after beginning of administration.	Sustained symptom resolution is defined as absences of symptoms (except for mild fatigue or mild cough) over at least 2 days.; Time to sustained symptom resolution is defined as the time from initiation of study treatment (active or placebo) until symptom resolution.	28 days
Secondary	Proportion of participants who experience any of these events within 14 and 28 days after beginning of administration.	COVID-19 related hospitalization (defined as > 24 hours of acute care).; COVID-19 related emergency room visit > 24 hours.; All-cause mortality.	up to Day 14 and 28
Secondary	Proportion of participants with clinical recovery of symptomatic reliefs within 7 days and 14 days after beginning of administration.	Clinical recovery is defined as subjects with normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 2 days.	up to Day 7 and 14
Secondary	Proportion of participants demonstrating improvement of each targeted symptom via participant questionnaire.	Improvement is defined as symptoms scored 2 or 3 at baseline are scored 0 or 1, AND symptoms scored 1 at baseline are scored 0.	up to Day 7, 14 and 28
Secondary	Proportion of participants demonstrating resolution of each targeted symptom via participant questionnaire.	Resolution is defined as symptoms (except tiredness and cough) scored = 1 at baseline are scored 0, AND tiredness or cough scored > 1 at baseline are scored = 1.	up to Day 7, 14 and 28
Secondary	Time to Clinical Recovery (TTCR).	TTCR is defined as the time from initiation of study treatment (active or placebo) until clinical recovery.	up to Day 7 and 14
Secondary	Time to improvement of each targeted symptom via participant questionnaire.	Time to improvement is defined as the time from initiation of study treatment (active or placebo) until this symptom meets the definition of improvement AND sustained for at least 2 days.	up to Day 7, 14 and 28
Secondary	Time to resolution of each targeted symptom via participant questionnaire.	Time to resolution is defined as the time from initiation of study treatment (active or placebo) until this symptom meets the definition of resolution AND sustained for at least 2 days.	up to Day 7, 14 and 28
Secondary	Viral load change	Viral load change from screening to Day 8 and 15	Day 8 and 15